XBiotech, a company involved in commercializing biological therapies, has published the results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston.
The study describes the outcome in 52 advanced cancer patients treated with their Xilonix™ non-cytotoxic, anti-tumor therapy. The so-called true human antibody therapy was reported to have an excellent safety profile and the report describes comprehensive measures of patient performance during therapy with Xilonix.
It was reported that overall, patients constitutional symptoms improved, including reduction in pain and fatigue. A highlight of the report was the finding that almost two-thirds of patients assessed with a new form of X-ray imaging demonstrated physical recovery of lean body mass (which is another way of referring to muscle mass) but moreover, that these same patients had dramatic improvement in overall survival.
The Company's lead product candidate, in Phase III clinical studies, is a novel, breakthrough treatment for advanced colorectal cancer
In an accompanying commentary, Dr. Charles Dinarello wrote, "The study is a unique contribution because it opens entire new areas in cancer therapeutics. The study also provides a rationale for early use of anti-cytokine therapy in cancer and sets the stage for use of anti-cytokine treatment in combination with kinase inhibitors and antiimmunosuppressive treatments."
Chairman&CEO added, "We are certainly happy to see these very important findings recognized in the world's premier cancer journal. I hope the wider dissemination of this scientific and clinical milestone helps drive the development of Xilonix therapy as well as others that work to control cancer using less toxic approaches."
Published in Lancet Oncology.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Artificial Intelligence: It's Time To Talk About What Emotions We Want AI To Have
- Highlights From ICNFP 2015
- Most Idiotic Rejection Of Course From Philosopher Of Science Not Grasping Relativity
- Lettuces Now, What Next - Could Astronauts Get All Their Oxygen And Food From Algae Or Plants?
- Supertranslations And Eternal Ghosts: Black Holes No Closer To Being Understood
- Innate GMO Potato Deregulated By USDA
- Brain Size Matters When It Comes To Remembering
- "Carney3 - when Columbus sailed to America - his boat was the results of several millennia of development..."
- "The ISS being used to do even more unnecessary human-factors research is a waste of time and money..."
- "I have a friend who has 2 Ph.D., one in nuclear physics and one in philosophy. His general observation..."
- "The top spin is indeed being measured, with results in agreement with standard model predictions..."
- "Without a magnetic field on Mars, it should be patently obvious that terraforming attempts would..."
- “Shock Therapy” – Not a Cuckoo’s Nest, a Valid Depression Rx
- Innate: Simplot genetically engineered potato gets USDA nod for deregulation
- Sorry, AIDS Deniers, It’s Only a Headline
- Mission Not Yet Accomplished on Vaccines
- Cigarettes, Now With An Organic Health Halo
- Bee Wary of Tales of the ‘Beepocalypse’
- Pollution and weather influence heart attack outcomes?
- Fish oil diet versus gut microbes
- Naps linked to reduced blood pressure and fewer medications
- Why girls are less interested in computer science: Classrooms are too 'geeky'
- Frogs make irrational choices - and what means for understanding animal mating